sought
develop
optim
hybridomabas
technolog
gener
human
hybridoma
secret
virusspecif
monoclon
antibodi
clinic
diagnosi
therapi
develop
novel
electrofus
protocol
effici
fuse
epsteinbarr
viru
ebv
transform
human
b
cell
myeloma
partner
test
seven
myeloma
cell
line
achiev
highest
effici
hmma
line
use
optim
electrofus
process
improv
cell
treatment
electrofus
well
vari
cell
ratio
fusion
medium
experiment
paramet
fusion
effici
increas
remark
signific
improv
effici
previou
pegbas
electrofus
method
use
optim
protocol
obtain
human
hybridoma
secret
fulli
human
monoclon
antibodi
two
major
human
respiratori
pathogen
respiratori
syncyti
viru
rsv
influenza
vaccin
viru
strain
conclus
develop
effici
routin
approach
gener
human
hybridoma
secret
function
human
virusspecif
monoclon
antibodi
human
monoclon
antibodi
mab
possess
mani
advantag
animalderiv
antibodi
clinic
applic
prevent
treatment
microbi
infect
immunotherapi
toxin
diagnosi
antibodytarget
radioisotop
imag
creation
human
hybridoma
cell
line
produc
immunoglobulin
fuse
human
b
cell
mous
myeloma
cell
first
report
schwaber
cohen
year
later
humanhuman
hybridoma
describ
bloom
nakamura
first
success
gener
human
mab
predefin
specif
report
olsson
kaplan
olsson
kaplan
success
fuse
human
spleen
cell
patient
hodgkin
diseas
human
myeloma
cell
despit
signific
number
human
mab
describ
current
method
isol
fulli
human
mab
ineffici
yield
unpredict
result
develop
reliabl
routin
method
gener
human
mab
face
number
obstacl
low
immunoglobulin
ig
product
capabl
fusion
rapid
loss
ig
product
chromosom
instabl
human
hybridoma
collect
antigenspecif
b
cell
first
import
step
human
hybridoma
gener
antigenspecif
cell
gener
rare
peripher
blood
fusion
effici
current
method
hybridoma
gener
suffici
immort
rare
cell
number
cell
obtain
routin
phlebotomi
steven
report
frequenc
b
cell
produc
antitetanu
igg
antibodi
circul
time
point
two
four
week
booster
inject
steven
et
al
low
frequenc
combin
fact
b
cell
usual
repres
less
peripher
blood
mononuclear
cell
pbmc
low
fusion
effici
current
fusion
method
order
suggest
chanc
obtain
antigenspecif
human
hybridoma
order
consequ
gener
human
hybridoma
cell
secret
desir
human
mab
proven
difficult
although
human
b
cell
immort
ebv
transform
casali
et
al
kozbor
roder
convent
ebvtransform
immort
restrict
subset
b
cell
result
mab
predominantli
igm
isotyp
moreov
ebvtransform
b
cell
gener
grow
poorli
usual
secret
low
amount
antibodi
also
difficult
clone
exhibit
chromosom
instabl
casali
et
al
crawford
ando
roder
et
al
steinitz
et
al
recent
studi
suggest
addit
cpg
transform
facilit
effici
transform
bernasconi
et
al
hartmann
krieg
traggiai
et
al
limit
number
suitabl
fusion
partner
hinder
develop
human
mab
hybridoma
technolog
mous
myeloma
origin
use
hybridoma
work
suitabl
deriv
human
mab
human
b
cell
heterospecif
hybrid
often
quickli
reject
relev
human
chromosom
investig
recent
isol
gener
new
myeloma
line
interest
human
hybridoma
work
one
new
murin
fusion
partner
cell
line
transform
coexpress
gene
encod
murin
human
telomeras
catalyt
subunit
htert
dessain
et
al
murin
directli
stimul
immunoglobulin
product
prolifer
hybridoma
human
tert
lengthen
telomer
synthesi
telomer
hexam
repeat
sequenc
therebi
provid
cell
unlimit
replic
capabl
promot
karyotyp
stabil
human
myeloma
cell
line
also
use
fusion
olsson
kaplan
brodin
et
al
cote
et
al
olsson
recent
isol
fulli
human
myeloma
design
karpa
karpa
et
al
final
anoth
class
fusion
partner
heterohybridoma
construct
fusion
murin
myeloma
cell
human
cell
exampl
hmma
posner
et
al
kirman
et
al
cell
line
although
line
yield
viabl
fusion
highli
effici
fusion
protocol
describ
studi
develop
optim
electrofus
techniqu
demonstr
hmma
optim
partner
cell
line
method
optim
condit
ebv
transform
paramet
electrofus
treatment
hybridoma
cell
line
cultur
overcam
inher
limit
current
technolog
routin
gener
human
hybridoma
moreov
employ
optim
protocol
success
gener
human
hybridoma
secret
fulli
human
mab
two
major
human
respiratori
pathogen
test
seven
differ
cell
line
myeloma
fusion
partner
summari
sourc
line
provid
tabl
detail
line
follow
everi
case
rpmi
medium
invitrogen
use
gentamicin
invitrogen
addit
addit
specifi
cell
line
atcc
kozbor
et
al
myelomalik
cell
line
gener
fuse
human
lymphoblastoid
cell
line
defici
hypoxanthin
phosphoribosyl
transferas
resist
ouabain
human
plasmacytoma
line
medium
cultur
cell
supplement
heatinactiv
fetal
bovin
serum
fb
mm
ouabain
mm
glutamin
atcc
brown
et
al
william
l
carrol
humanmous
heterohybridoma
produc
fuse
myeloma
cell
malign
lymphoid
cell
isol
patient
nodular
lymphoma
cultur
medium
supplement
fb
mm
glutamin
karpa
karpa
et
al
fulli
human
myeloma
cell
line
establish
patient
multipl
myeloma
cultur
medium
supplement
fb
mm
glutamin
atcc
teng
et
al
gener
fuse
human
myeloma
cell
line
mous
myeloma
cell
line
cultur
medium
supplement
fb
mm
glutamin
htert
dessain
et
al
deriv
murin
myeloma
cell
line
modifi
ectop
express
murin
human
telomeras
htert
cultur
medium
supplement
fb
mm
glutamin
mm
sodium
pyruv
hmma
subclon
select
passag
line
clone
limit
dilut
select
clone
optim
fusion
effici
parent
line
gener
fusion
mous
myeloma
cell
line
bone
marrow
mononuclear
cell
patient
iga
myeloma
posner
et
al
cultur
medium
supplement
fb
mm
glutamin
mm
nonessenti
amino
acid
mm
sodium
pyruv
kirman
et
al
trioma
gener
fuse
murin
myeloma
cell
line
human
myeloma
cell
line
yield
intermedi
heteromyeloma
follow
fusion
human
lymphocyt
medium
supplement
cosmic
calf
serum
hyclon
mm
glutamin
mm
nonessenti
amino
acid
mm
sodium
pyruv
vitamin
pbmc
obtain
donor
blood
ficol
densiti
gradient
centrifug
histopaqu
sigma
st
loui
mo
human
lymphocyt
stimul
transform
use
tlr
agonist
cpg
odn
odn
coley
pharmaceut
group
canada
supernat
persist
infect
transform
cell
atcc
contain
epstein
barr
viru
total
cell
cultur
co
monitor
microscop
inspect
transform
appear
cell
cluster
pegmedi
fusion
perform
use
convent
techniqu
briefli
myeloma
cell
ebvtransform
human
b
cell
wash
medium
first
wash
dpb
without
calcium
magnesium
invitrogen
prewarm
roch
diagnost
indianapoli
ad
cell
pellet
resuspens
dropwis
manner
follow
dropwis
addit
ml
ad
ml
incub
suspens
co
five
minut
fuse
cell
wash
medium
resuspend
select
medium
contain
hypoxanthin
aminopterinthymidin
hat
sigma
seed
plate
densiti
approxim
transform
b
cellswel
electrofus
system
use
apparatu
electrod
fusion
chamber
cyto
puls
scienc
inc
fusion
volum
myeloma
cell
ebvtransform
human
b
cell
wash
cytofus
medium
cyto
puls
scienc
inc
instrument
set
follow
prefus
dielectrophoresi
perform
second
altern
current
voltag
mhz
cell
electropor
singl
squarewav
highvoltag
direct
current
puls
last
millisecond
puls
frequenc
voltag
test
includ
singl
puls
multipl
puls
differ
decreas
voltag
postfus
dielectrophoresi
accomplish
second
use
altern
current
voltag
mhz
fusion
cell
allow
recov
fusion
electrod
minut
room
temperatur
harvest
wash
prior
plate
multiwel
plate
cultur
fusion
cell
seed
micropl
approxim
b
cell
per
well
exampl
total
cell
myeloma
b
cell
ratio
use
fusion
complet
medium
contain
heatinactiv
fb
amphotericin
b
mm
lglutamin
mm
sodium
pyruv
gentamicin
tylosin
solut
hypoxanthin
aminopterin
thymidin
hat
sigma
ouabain
seven
day
cultur
cell
fed
remov
cultur
medium
follow
addit
equal
volum
fresh
medium
contain
hypoxanthin
thymidin
ht
sigma
number
independ
coloni
well
count
day
fusion
fusion
effici
percentag
basi
calcul
total
number
hybridoma
coloni
well
divid
number
input
b
cell
multipli
total
well
assess
condit
initi
screen
immunoglobulin
ig
product
enzymelink
immunosorb
assay
elisa
hybridoma
cell
posit
well
expand
plate
cultur
rpmi
contain
heatinactiv
fb
mm
glutamin
mm
sodium
pyruv
gentamicin
supernat
expand
line
test
specif
use
antigenspecif
elisa
posit
hybridoma
cell
subclon
serial
limit
dilut
plate
cellperwel
densiti
cellperwel
limit
dilut
perform
twice
ensur
gener
clone
cultur
supernat
screen
separ
elisa
total
human
ig
human
igg
antigenspecif
antibodi
detect
human
ig
igg
immulon
microtit
plate
precoat
unlabel
goat
antihuman
antibodi
detect
heavyand
lightchain
hl
ig
molecul
southern
biotechnolog
associ
birmingham
al
incub
overnight
well
block
dpb
contain
nonfat
milk
goat
serum
room
temperatur
two
hour
plate
wash
dpb
contain
wash
supernat
ad
well
incub
two
hour
room
temperatur
human
ig
detect
alkalin
phosphataseconjug
goat
antihuman
ig
hl
southern
biotechnolog
associ
birmingham
al
use
secondari
antibodi
detect
human
igg
alkalin
phosphataseconjug
goat
antihuman
igg
fragmentspecif
antibodi
jackson
immunoresearch
use
secondari
antibodi
enzymat
reaction
perform
phosphatas
substrat
tablet
sigma
trishcl
mm
mgcl
substrat
buffer
antirsv
f
protein
elisa
plate
precoat
purifi
recombin
rsv
f
protein
incub
overnight
block
dpb
contain
bsa
goat
serum
room
temperatur
hour
influenza
antigen
elisa
plate
precoat
strain
vaccin
antigen
incub
overnight
block
dpb
contain
nonfat
milk
goat
serum
room
temperatur
hour
subsequ
step
bind
assay
fulli
clone
hybridoma
line
test
level
product
igg
cell
cultur
stationeri
flask
densiti
cell
per
ml
complet
medium
co
supernat
collect
hour
time
point
quantif
human
ig
captur
elisa
assay
signal
compar
gener
standard
curv
purifi
human
igg
product
calcul
amount
antibodi
produc
percel
perhour
basi
establish
optim
drug
treatment
condit
select
human
hybridoma
determin
sensit
resist
drug
select
transform
b
cell
myeloma
fusion
partner
cell
line
ouabain
resistanceconvent
primari
b
cell
die
prolong
cultur
transform
b
cell
surviv
prolong
cultur
hat
select
human
cell
sensit
ouabain
select
therefor
select
human
hybridoma
carri
presenc
ouabain
elimin
nonfus
ebvtransform
b
cell
test
sensit
ebvtransform
human
b
cell
differ
concentr
ouabain
found
minimum
concentr
kill
ebvtransform
human
b
cell
ebvtransform
b
cell
kill
seven
day
cultur
medium
contain
ouabain
fig
test
resist
seven
myeloma
fusion
partner
cell
line
ouabain
result
show
htert
hmma
cell
line
grew
normal
seven
day
exposur
ouabain
line
found
secret
human
light
chain
constitut
data
shown
elimin
consider
partner
cell
candid
approxim
cell
karpa
cell
surviv
seven
day
select
fig
although
literatur
suggest
cell
resist
ouabain
found
preliminari
experi
line
sensit
ouabain
evalu
sinc
ouabain
resist
requir
select
hybridoma
follow
fusion
ebvtransform
b
cell
hat
resistancew
test
resist
sensit
myeloma
partner
cell
line
medium
contain
hat
found
cell
line
sensit
drug
combin
ebvtransform
b
cell
resist
hat
select
medium
data
shown
therefor
htert
hmma
cell
found
prefer
featur
use
work
name
nonsecret
ouabainresist
hatsensit
line
three
line
use
partner
cell
line
subsequ
fusion
studi
select
medium
final
formul
hat
plu
ouabain
synthet
oligodeoxynucleotid
odn
contain
immunostimulatori
cpg
motif
trigger
immunomodulatori
cascad
involv
b
cell
natur
killer
cell
profession
antigenpres
cell
ad
cpg
odn
ebv
transform
medium
human
b
cell
confirm
addit
cpg
odn
ebv
transform
perform
tissu
cultur
flask
significantli
enhanc
effici
transform
shorten
transform
time
five
ten
day
order
enrich
percentag
antigenspecif
b
cell
number
prefus
b
cell
sampl
transform
smaller
number
human
b
cell
multipl
well
plate
use
cpg
ebv
tabl
result
indic
addit
cpg
remark
increas
effici
ebv
transform
human
b
cell
compar
rel
fusion
abil
three
partner
cell
line
htert
hmma
form
hybridoma
cell
ebvtransform
human
b
lymphocyt
first
compar
fusion
effici
differ
myeloma
partner
cell
line
batch
ebvtransform
human
b
cell
fig
compar
fusion
effici
particular
partner
cell
line
differ
batch
ebvtransform
human
b
cell
tabl
electrofus
protocol
appli
use
singl
dc
puls
total
transform
b
cell
use
fusion
cell
ratio
partner
cell
transform
b
cell
hybridoma
cell
select
medium
contain
hat
plu
ouabain
seven
day
plate
number
hybridoma
coloni
condit
count
day
cultur
fusion
result
suggest
hmma
suitabl
partner
cell
line
gener
human
hybridoma
cell
electrofus
use
therefor
use
cell
line
optim
electrofus
protocol
studi
obtain
addit
partner
line
report
ideal
partner
cell
line
direct
fusion
human
b
cell
kirman
et
al
potenti
line
fusion
partner
cell
ebvtransform
human
b
cell
report
therefor
includ
partner
cell
line
candid
compar
fusion
effici
hmma
pegmedi
fusion
electrofus
protocol
follow
ouabain
select
approxim
cell
surviv
seven
day
therefor
transfect
ouabainresist
gene
cell
line
seek
increas
cell
resist
ouabain
select
compar
fusion
effici
pbmc
either
engin
line
hmma
cell
cell
exhibit
higher
fusion
effici
pbmc
pegmedi
fusion
electrofus
tabl
howev
fuse
ebvtransform
human
b
cell
hmma
effici
line
twoto
threefold
higher
effici
engin
cell
use
electrofus
tabl
notabl
electrofus
method
yield
overal
higher
hybridoma
yield
pegmedi
fusion
therefor
select
hmma
optim
partner
cell
subsequ
experi
test
whether
multipl
direct
current
electr
puls
could
enhanc
overal
fusion
effici
hmma
cell
fuse
ebvtransform
human
b
cell
compar
effect
singl
multipl
puls
overal
fusion
effici
decreas
slightli
use
multipl
puls
compar
singl
puls
procedur
fig
addit
altern
current
wave
multipl
puls
hold
b
cell
myeloma
cell
contact
prior
repeat
puls
affect
reduct
fusion
effici
fig
neg
effect
like
due
increas
lysi
myeloma
partner
cell
follow
multipl
puls
use
singl
puls
subsequ
experi
investig
whether
cocultur
hybridoma
cell
immedi
fusion
would
enhanc
recoveri
viabl
hybridoma
cell
line
shown
previous
cocultur
primari
human
b
cell
murin
thymoma
cell
fibroblast
cell
express
human
ligand
enhanc
prolifer
differenti
antibodi
secret
b
cell
cultur
weitkamp
et
al
cultur
condit
gamma
irradi
procedur
cell
describ
previous
electrofus
perform
use
hmma
partner
cell
ebvtransform
human
b
cell
fusion
plate
three
type
cultur
plate
without
feeder
cell
cell
per
well
irradi
cell
cell
per
well
irradi
fibroblast
determin
effect
feeder
cell
growth
human
hybridoma
cell
determin
number
coloni
form
fusion
equal
portion
fusion
reaction
cultur
three
condit
result
show
feeder
cell
increas
number
hybridoma
gener
treatment
singl
multipl
electrofus
puls
fig
condit
cell
handl
fusion
could
affect
effici
hybridoma
format
sought
optim
addit
paramet
could
affect
hybridoma
yield
significantli
wash
intens
wash
buffer
incub
time
handl
condit
convent
treatment
use
pb
wash
optim
treatment
transform
b
cell
partner
cell
wash
separ
fresh
medium
follow
three
wash
fusion
medium
complet
remov
protein
medium
addit
alter
conduct
properti
fusion
medium
fusion
ad
recoveri
incub
period
minut
cell
fusion
chamber
co
collect
plate
multiwel
plate
modifi
preand
postfus
cell
treatment
overal
fusion
effici
increas
threefold
compar
fusion
effici
electrofus
protocol
pegmedi
fusion
use
batch
ebvtransform
human
b
cell
hmma
cell
hybridoma
product
use
optim
electrofus
protocol
coupl
optim
cell
treatment
threefold
increas
convent
peg
fusion
fig
although
fusion
effici
observ
peg
techniqu
significantli
better
effici
previous
report
steenbakk
et
al
electrofus
protocol
still
perform
superior
manner
mechan
cell
fusion
caus
peg
electrofus
differ
significantli
deliveri
high
voltag
direct
current
puls
deliv
high
level
energi
cell
field
result
pore
format
plasma
cell
membran
effici
pore
format
depend
energi
deliv
cell
correspond
part
cell
size
electropor
effici
larg
myeloma
cell
smaller
b
cell
electr
paramet
sinc
possibl
optim
cell
ratio
myeloma
b
cell
differ
two
method
investig
effici
fusion
use
vari
cell
ratio
result
show
optim
cell
ratio
electrofus
pegmedi
fusion
differ
previou
work
shown
myeloma
human
b
cell
ratio
optim
cell
ratio
peg
fusion
method
data
shown
electrofus
hmma
myeloma
cell
human
pbmc
vari
ratio
reveal
partner
cell
pbmc
ratio
effici
hybridoma
format
compar
ratio
optim
peg
fusion
perform
seri
addit
experi
differ
cell
ratio
myeloma
cell
transform
human
b
cell
result
show
optim
cell
ratio
electrofus
ratio
increas
number
ebvtransform
b
cell
fusion
increas
fusion
effici
remark
tabl
experi
demonstr
cell
ratio
critic
factor
affect
fusion
effici
myeloma
cell
transform
human
b
cell
ratio
effici
electrofus
protocol
princip
goal
human
hybridoma
technolog
gener
cell
line
secret
antibodi
specif
target
medic
interest
sought
demonstr
util
effici
optim
electrofus
protocol
gener
antibodi
specif
surfac
glycoprotein
two
pathogen
human
respiratori
virus
first
target
address
respiratori
syncyti
viru
rsv
fusion
f
protein
valid
target
prophylaxi
highrisk
human
infant
pbmc
isol
healthi
adult
donor
b
cell
transform
use
ebv
cpg
fuse
hmma
myeloma
cell
use
final
optim
electrofus
protocol
result
fusion
distribut
multiwel
plate
supernat
harvest
coloni
form
well
day
test
bind
rsv
f
protein
use
f
protein
elisa
fig
identifi
hybridoma
line
secret
antirsv
f
protein
human
mab
clone
line
limit
dilut
yield
clone
design
purifi
antibodi
secret
clone
bound
strongli
rsv
f
protein
fig
second
target
chose
surfac
glycoprotein
vaccin
influenza
viru
ebvtransform
b
cell
previous
immun
healthi
adult
donor
hmma
myeloma
cell
fuse
use
optim
fusion
protocol
sever
human
hybridoma
cell
line
secret
mab
identifi
clone
two
design
fig
result
elisa
bind
assay
show
bind
activ
human
mab
antigen
high
specif
fig
sequenc
analysi
antibodi
variabl
region
gene
reveal
two
clone
ident
goal
hybridoma
format
gener
product
igg
protein
test
differ
human
hybridoma
clone
cell
line
made
optim
method
level
product
igg
cultur
amount
igg
produc
measur
captur
elisa
compar
bind
signal
standard
curv
produc
test
dilut
seri
highli
purifi
human
igg
known
concentr
normal
product
level
valu
percel
perhour
basi
product
level
vari
cell
line
best
level
picogram
igg
per
hour
per
cell
averag
product
level
picogram
igg
per
hour
per
cell
studi
defin
optim
protocol
gener
human
mabsecret
hybridoma
cell
line
demonstr
protocol
valuabl
practic
routin
gener
human
mabsecret
hybridoma
incorpor
higheffici
ebvtransform
use
cpg
treatment
determin
hmma
suitabl
partner
cell
line
seven
myeloma
cell
line
improv
paramet
electrofus
achiev
remark
enhanc
effici
fusion
gener
viabl
hybridoma
use
ebvtransform
human
b
cell
fusion
increas
hybrid
format
much
compar
use
untransform
pbmc
kozbor
et
al
howev
minor
b
cell
deriv
peripher
blood
lymphocyt
infect
ebv
use
receptor
molecul
present
subset
b
cell
infect
cell
immort
sugden
mark
recent
found
addit
cpg
oligonucleotid
ebv
transform
medium
increas
effici
b
cell
immort
bernasconi
et
al
hartmann
krieg
traggiai
et
al
cpg
odn
intern
rapidli
immun
cell
interact
tolllik
receptor
activ
cell
initi
immunostimulatori
cascad
klinman
result
confirm
addit
cpg
oligonucleotid
ebv
transform
significantli
increas
transform
effici
procedur
also
reduc
time
requir
transform
natur
fusion
partner
critic
determin
effici
gener
human
hybridoma
use
number
partner
interest
featur
determin
optim
cell
line
use
electrofus
line
exhibit
limit
fusion
experi
use
karpa
found
cell
line
exhibit
low
fusion
effici
weak
resist
ouabain
cell
line
highli
resist
ouabain
line
secret
human
ig
chain
interfer
mab
product
line
effici
fuse
nontransform
human
b
cell
howev
show
highest
effici
fusion
achiev
use
ebvtransform
cell
hmma
line
hmma
humanmous
cell
line
gener
fuse
mous
myeloma
cell
line
bone
marrow
mononuclear
cell
patient
iga
myeloma
posner
et
al
use
partner
cell
line
averag
fusion
effici
one
fuse
cell
achiev
fuse
human
pbmc
pokewe
mitogenstimul
pbmc
ebvtransform
polyclon
b
cell
employ
hmma
number
hybridoma
secret
human
antitetanu
monoclon
igm
igg
antibodi
clone
earlier
studi
support
predict
fusion
heterohybridoma
cell
line
human
lymphocyt
would
yield
stabl
hybridoma
raison
et
al
electr
fieldinduc
cell
fusion
techniqu
report
zimmermann
vienken
electrofus
number
theoret
advantag
pegmedi
fusion
effici
electrofus
consider
higher
peg
fusion
peg
fusion
averag
fusion
effici
wherea
previou
method
electrofus
achiev
effici
foung
perkin
glassi
ohnishi
et
al
schmitt
et
al
steenbakk
et
al
vienken
zimmermann
zimmermann
vienken
theoret
electrofus
appli
induc
hybrid
format
two
cell
howev
success
electrofus
depend
natur
fusion
partner
type
state
activ
b
cell
electrofus
paramet
need
optim
particular
cell
use
high
degre
heterogen
differ
fusion
partner
cell
even
subpopul
within
particular
cell
popul
growth
condit
concentr
co
growth
medium
composit
state
b
cell
activ
affect
hybridoma
format
effici
zimmermann
et
al
histor
electrofusionmedi
effici
myeloma
human
b
cell
quit
low
exampl
fusion
effici
hmma
precursor
previous
describ
posner
et
al
studi
optim
condit
hybridoma
product
iter
fashion
increas
fusion
effici
effici
quit
high
prove
effect
gener
human
mab
human
respiratori
tract
pathogen
even
subject
recent
infect
immun
optim
protocol
offer
effect
approach
gener
desir
fulllength
human
mab
two
ebvtransform
b
cell
line
separ
donor
plate
plate
complet
medium
plu
differ
concentr
ouabain
cell
plate
well
total
cell
assess
livedead
statu
use
trypan
blue
dye
exclus
day
plate
condit
replic
column
repres
averag
percentag
live
cell
error
bar
repres
sd
five
partner
cell
line
test
resist
ouabain
cell
line
cultur
medium
plu
ouabain
plate
well
initi
contain
cell
total
cell
assess
livedead
statu
use
trypan
blue
dye
exclus
day
plate
condit
replic
column
repres
averag
percentag
live
cell
error
bar
repres
sd
suspens
contain
cell
hmma
cell
line
fuse
individu
cell
singl
line
ebvtransform
human
b
cell
fusion
distribut
well
plate
receiv
b
cell
fusion
product
select
hat
plu
ouabain
treatment
five
day
fusion
effici
calcul
count
total
number
coloni
well
divid
number
input
b
cell
multipli
total
well
assess
condit
column
repres
averag
percentag
fusion
effici
two
experi
error
bar
repres
sd
total
hmma
cell
fuse
ebvtransform
b
cell
fusion
product
select
hat
plu
ouabain
five
day
plate
ac
stand
altern
current
dc
direct
current
electr
element
protocol
shown
order
indic
puls
use
group
indic
puls
omit
number
result
hybridoma
coloni
count
week
fusion
fusion
effici
determin
fig
experi
white
experi
black
column
repres
averag
fusion
effici
two
fusion
error
bar
repres
sd
hmma
cell
fuse
ebvtransform
human
b
cell
use
previous
determin
optim
electrofus
paramet
test
effect
optim
cell
treatment
condit
electrofus
detail
descript
result
section
electrofus
also
compar
peg
fusion
cell
ratio
peg
fusion
partner
cell
transform
b
cell
electrofus
input
number
ebvtransform
b
cell
experi
hybridoma
select
coloni
count
perform
way
previou
experi
column
repres
averag
fusion
effici
two
experi
error
bar
repres
sd
total
ebvtransform
human
b
cell
hmma
partner
cell
fuse
use
electrofus
method
supernat
hybridoma
line
appear
week
cell
fusion
select
hat
ouabain
screen
rsv
fspecif
elisa
human
rsvimmun
serum
use
posit
control
medium
block
buffer
use
determin
background
signal
total
ebvtransform
human
b
cell
hmma
partner
cell
fuse
use
electrofus
method
supernat
hybridoma
line
appear
week
cell
fusion
select
hat
ouabain
screen
elisa
hybridoma
well
score
posit
optic
densiti
exceed
threshold
increas
threefold
background
indic
dot
line
clone
determin
preliminari
screen
cell
line
subclon
incub
wellplat
week
abil
clone
test
elisa
neg
control
antibodi
antirsv
f
human
mab
shown
fig
day
cultur
follow
initi
ebv
transform
fusion
effici
use
pegmedi
electrofus
method
fuse
pbmc
hmma
partner
cell
line
two
independ
fusion
tabl
note
estim
pbmc
b
cell
actual
fusion
effici
b
cell
higher
nt
test
tabl
fusion
ebvtransform
b
cell
use
fusion
fusion
dispers
plate
fusion
effici
calcul
specifi
tabl
fusion
effici
calcul
specifi
tabl
